miRCURY LNA™ microRNA Antisense Controls

Negative control inhibitors for quality assessment of your in vitro microRNA inhibition experiment

Niels M. Frandsen, Ph.D., Product Manager Back

Similar in length of sequence and LNA™ design to our miRCURY LNA™ microRNA Inhibitor and Power Inhibitor
No homology to any known microRNA or mRNA sequences in mouse, rat or human

Coverage

We currently offer four pre-designed negative controls for the miRCURY LNA™ microRNA Inhibitors - two miRCURY LNA™ microRNA Inhibitor Negative Controls and two miRCURY LNA™ microRNA Power Inhibitor Negative Controls with the phosphorothioate backbone to match the miRCURY LNA™ microRNA Power Inhibitors.

For each of the inhibitor product categories we have the following two microRNA inhibitor control offerings:

Negative Control A (identical to the former Scramble-miR control): No hits of >70% homology to any sequence in any organism in the NCBI and miRBase databases.

Negative Control B (identical to the former Sense miR-159 control): No hits of >70% homology to any human, mouse or rat sequence in the NCBI and miRBase databases. Not recommended for use in plants.

All microRNA inhibitor controls are available as ready-to-label or as pre-labeled 3’ and 5’ fluorescein (6-FAM) oligonucleotides similar to the miRCURY LNA™ microRNA Inhibitors and Power Inhibitors. The controls are HPLC-purified and desalted and delivered in tubes containing 5 nmol dried-down oligonucleotide ready for transfection or electroporation using standard techniques.

Note

For information on how to design your own microRNA inhibitor control, please go to Custom miRCURY LNA™ microRNA Inhibitors.

To view the sequences of the microRNA inhibitor controls, please click on your product of interest in the table below.

View experimental data on the miRCURY LNA™ microRNA Inhibitors and Power Inhibitors

"...thanks to the LNA™ microRNA inhibitor screen, we have discovered several new miRNAs playing a major role in the regulation of the proliferation/differentiation balance in prostate cells."

Dr. Xavier Gidrol directs the Biomics Laboratory at the Institute of Life Science Research and Technologies in Grenoble, France. They use microfluidics, micromanufacturing and MEMS to study the impact of genetic and micro-environmental determinants on carcinogenesis, at the scale of a few or even single cells. Xavier has used minute cell microarrays to perform high throughput and high content screening with our human library of microRNA inhibitors in primary prostate cancer cells extracted from patients.

Read full story...

"Previously, we had tried other inhibitor designs but these gave inconclusive results"

Amy Hansen is a Ph.D student at the University College London. She works in the Cancer Research UK Viral Oncology Group lead by Professor Chris Boshoff, Director of the UCL Cancer Institute.

Read full story...

"LNA microRNA antisense inhibitors are efficient and specific with long lasting effects"

Dr. Annick Harel-Bellan (AHB) is Directeur de Recherche at the Institut Andre Lwoff in Paris. She heads a group working on epigenetics and cancer (Laboratoire Epigenetique et Cancer). Dr. Anna Polesskaya (AP) is a senior scientist and longstanding member of this group

Read full story...